Literature DB >> 23403631

Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET?

Joseph H McCarty1.   

Abstract

In glioblastoma cells the receptor tyrosine kinase c-Met is upregulated in response to bevacizumab and plays an important role in promoting invasion and tumor recurrence. These data support novel links between VEGF-A and hepatocyte growth factor and suggest that c-Met and its signaling effectors may be effective targets for anti-invasive therapies. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23403631      PMCID： PMC3618531          DOI： 10.1158/1078-0432.CCR-13-0051

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

Review 2.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

3.  VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

Authors:  Weon-Kyoo You; Barbara Sennino; Casey W Williamson; Beverly Falcón; Hiroya Hashizume; Li-Chin Yao; Dana T Aftab; Donald M McDonald
Journal:  Cancer Res       Date:  2011-05-25       Impact factor: 12.701

Review 4.  Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

Authors:  Basel Sitohy; Janice A Nagy; Harold F Dvorak
Journal:  Cancer Res       Date:  2012-04-15       Impact factor: 12.701

5.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

Authors:  Kan V Lu; Jeffrey P Chang; Christine A Parachoniak; Melissa M Pandika; Manish K Aghi; David Meyronet; Nadezda Isachenko; Shaun D Fouse; Joanna J Phillips; David A Cheresh; Morag Park; Gabriele Bergers
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

6.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 7.  Making a tumour's bed: glioblastoma stem cells and the vascular niche.

Authors:  Richard J Gilbertson; Jeremy N Rich
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

Review 8.  Angiogenesis in brain tumours.

Authors:  Rakesh K Jain; Emmanuelle di Tomaso; Dan G Duda; Jay S Loeffler; A Gregory Sorensen; Tracy T Batchelor
Journal:  Nat Rev Neurosci       Date:  2007-08       Impact factor: 34.870

9.  Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Authors:  Arman Jahangiri; Michael De Lay; Liane M Miller; W Shawn Carbonell; Yu-Long Hu; Kan Lu; Maxwell W Tom; Jesse Paquette; Taku A Tokuyasu; Sean Tsao; Roxanne Marshall; Arie Perry; Kirsten M Bjorgan; Myriam M Chaumeil; Sabrina M Ronen; Gabriele Bergers; Manish K Aghi
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

10.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

Authors:  John F de Groot; Gregory Fuller; Ashok J Kumar; Yuji Piao; Karina Eterovic; Yongjie Ji; Charles A Conrad
Journal:  Neuro Oncol       Date:  2010-01-06       Impact factor: 12.300
View more
  19 in total

Review 1.  Treatment options for recurrent high-grade gliomas.

Authors:  Harjus S Birk; Seunggu J Han; Nicholas A Butowski
Journal:  CNS Oncol       Date:  2016-12-21

2.  A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery.

Authors:  Xingmei Zhang; Huiyu Liang; Yan Tan; Xidong Wu; Shuji Li; Yusheng Shi
Journal:  Biomed Rep       Date:  2014-05-15

3.  Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression.

Authors:  P A Guerrero; J H Tchaicha; Z Chen; J E Morales; N McCarty; Q Wang; E P Sulman; G Fuller; F F Lang; G Rao; J H McCarty
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

4.  Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.

Authors:  Sonam Dilwali; Daniel Roberts; Konstantina M Stankovic
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  The Cytoskeletal Adapter Protein Spinophilin Regulates Invadopodia Dynamics and Tumor Cell Invasion in Glioblastoma.

Authors:  Mujeeburahiman Cheerathodi; Naze G Avci; Paola A Guerrero; Leung K Tang; Julia Popp; John E Morales; Zhihua Chen; Amancio Carnero; Frederick F Lang; Bryan A Ballif; Gonzalo M Rivera; Joseph H McCarty
Journal:  Mol Cancer Res       Date:  2016-09-21       Impact factor: 5.852

6.  Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.

Authors:  Carlos Bais; Barbara Mueller; Mark F Brady; Robert S Mannel; Robert A Burger; Wei Wei; Koen M Marien; Mark M Kockx; Amreen Husain; Michael J Birrer
Journal:  J Natl Cancer Inst       Date:  2017-11-01       Impact factor: 13.506

7.  Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme.

Authors:  Ramcharan Singh Angom; Sujan Kumar Mondal; Fei Wang; Vijay Sagar Madamsetty; Enfeng Wang; Shamit K Dutta; Yash Gulani; Rachel Sarabia-Estrada; Jann N Sarkaria; Alfredo Quiñones-Hinojosa; Debabrata Mukhopadhyay
Journal:  Oncogene       Date:  2020-10-01       Impact factor: 9.867

Review 8.  Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial.

Authors:  Shingo Takano; Eiichi Ishikawa; Kei Nakai; Masahide Matsuda; Tomohiko Masumoto; Tetsuya Yamamoto; Akira Matsumura
Journal:  Onco Targets Ther       Date:  2014-09-05       Impact factor: 4.147

Review 9.  Targeting tumor vasculature through oncolytic virotherapy: recent advances.

Authors:  Marcela Toro Bejarano; Jaime R Merchan
Journal:  Oncolytic Virother       Date:  2015-11-11

10.  Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling.

Authors:  Goparaju Chandrika; Kumar Natesh; Deepak Ranade; Ashish Chugh; Padma Shastry
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.